Figure 6.

CD8⁺ T cells are required for cabozantinib-induced inhibition of tumor growth. (A) Tumor growth inhibition by cabozantinib in wild type (WT) BALB/c and BALB/c Nude mice. 5×10⁶ Renca cells were subcutaneously inoculated into the right flank of WT BALB/c and BALB/C Nude mice. Seven days after tumor inoculation, mice (n=5 per group) received either vehicle or cabozantinib (10 mg/kg, once per day by gavage) treatment for 13 days. (B) Tumor growth inhibition rates by cabozantinib treatment in WT BALB/c and BALB/c Nude mice. This experiment was repeated 3 times. The results of one representative experiment are shown. (C) Schematic diagram of the experimental design. Mice were subcutaneously inoculated with Renca cells (day 0). At day 6 (one day before cabozantinib treatment), mice were randomly assigned to 4 groups (n=6 for each group) and received antibodies treatment as indicated: vehicle + isotype, cabozantinib + isotype control, vehicle + anti-CD8-depleting antibody and cabozantinib + anti-CD8-depleting antibody. (D) Representative FACS plot showing CD8⁺ T cells in peripheral blood 24 hours after intraperitoneal injection of anti-CD8 depleting antibody. (E) The tumor growth curve of each group during treatment. This experiment (C-E) was repeated 2 times. The results of one representative experiment are shown. *P<0.05, **P<0.01, by unpaired t-test; ns, not significant.